Active gastrointestinal disease or other malabsorption syndromes
Any malabsorption problem that, in the investigator's opinion, would prevent adequate absorption of the study drug
History of malabsorption or other condition that would interfere with absorption of study drugs
Any malabsorption condition
Malabsorption condition that would alter the absorption of orally administered medications
Any malabsorption condition
Any malabsorption condition
Malabsorption syndrome or other conditions that would interfere with intestinal absorption
Any malabsorption condition
History of known malabsorption syndrome or prior surgery(ies) that may lead to malabsorption
Malabsorption condition that would alter the absorption of orally administered medications
History of malabsorption or other condition that would interfere with absorption of cobimetinib.
Any malabsorption condition
Clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels. For example, subjects should have no more than 50% of the large intestine removed and no sign of malabsorption (e.g. gastrectomy, ileal bypass, chronic diarrhea, Crohn’s disease, malabsorption, gastroparesis).
Any malabsorption condition
malabsorption syndromes
Any malabsorption problem
Patients must not have clinically significant malabsorption syndrome or history
History of malabsorption or other condition that would interfere with absorption of vemurafenib
Known or suspected malabsorption condition or obstruction
Patients with hypercalcemia and/or any condition resulting in malabsorption
Malabsorption syndrome or other condition that would interfere with intestinal absorption are excluded
Any malabsorption condition.
Known or suspected malabsorption condition or obstruction; Note: Use of pancreatic enzyme supplements is allowed to control malabsorption
Suspected malabsorption or obstruction; note: use of pancreatic enzyme supplements is allowed to control malabsorption
Any malabsorption condition
Malabsorption syndrome, such as Crohn’s disease
Any malabsorption problem
History or current evidence of malabsorption or liver disease that would impair the absorption of itraconazole
Any malabsorption condition
Clinically significant malabsorption syndrome
Known or suspected malabsorption condition or obstruction
Patients with malabsorption or any other condition that in the opinion of the principal investigator could cause difficulty in absorption of drug
Clinically significant malabsorption syndrome
Any malabsorption condition
Malabsorption syndrome or other condition that would interfere with intestinal absorption
Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption
Any malabsorption problem
Any malabsorption condition
Malabsorption, total gastric resection
Presence of a malabsorption syndrome possibly affecting drug absorption (e.g., Crohn’s disease or chronic pancreatitis)
Have malabsorption syndrome or other gastrointestinal (GI) illness or condition.
Any malabsorption condition.
Any malabsorption condition
Any malabsorption condition.
Any malabsorption condition
History of current evidence of malabsorption or liver disease
Any malabsorption condition
Any malabsorption condition
Any malabsorption condition
Any malabsorption condition
Any malabsorption problem
PHASE I: Clinically significant malabsorption syndrome
Malabsorption syndrome or other conditions that would interfere with intestinal absorption
Any malabsorption condition
Any malabsorption condition
Malabsorption problem that may limit or inhibit the absorption of MEK162
Any malabsorption condition
Patients unable to take oral drugs or with known malabsorption syndromes
Any malabsorption condition
No known malabsorption syndrome
Any malabsorption conditions
Any malabsorption condition which, in the opinion of the treating physician, will affect the absorption of any of the agents used in this study.
History of malabsorption or other condition that would interfere with absorption of vemurafenib/cobimetinib
Any malabsorption condition that in the opinion of the investigator would significantly impact drug absorption
Any malabsorption condition that in the opinion of the investigator would significantly impact drug absorption
A history of malabsorption or other condition that would interfere with absorption of vemurafenib or cobimetinib.
Malabsorption syndrome or other condition that would interfere with enteric absorption
Patients with uncontrolled malabsorption syndromes
Any malabsorption condition
Malabsorption syndrome
Malabsorption ;
Any malabsorption problem
Any malabsorption problem
Any malabsorption problem
Any malabsorption problem
Subjects with gastrointestinal conditions which might result in malabsorption of the study drug
Any malabsorption disease/syndrome
